Gubra ASSTU:PI3 -3.11%56 Altman Z-Score is 27.80 as of Jun. 27, 2026, which is 28% below its 10-year median of 38.73. GuruFocus rates STU:PI3 with a GF Score™ of 56/100 and a GF Value™ of €381.59 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 934 Biotechnology companies, Gubra AS ranks better than 91.22% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 28.71 is strong.
Gubra AS has a Altman Z-Score of 27.80, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Gubra AS's Altman Z-Score or its related term are showing as below:
STU:PI3'
s Altman Z-Score Range Over the Past 10 Years
Min: 10.43 Med: 38.73 Max: 39.73
Current: 28.71
During the past 7 years, Gubra AS's highest Altman Z-Score was 39.73. The lowest was 10.43. And the median was 38.73.
Gubra AS (STU:PI3) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Gubra AS Altman Z-Score Related Terms
Gubra AS Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Gubra AS's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:PI3 vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, Gubra AS's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gubra AS Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gubra AS's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Gubra AS's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Gubra AS's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.8145
+
1.4
*
0.8558
+
3.3
*
1.6375
+
0.6
*
30.3689
+
1.0
*
1.9978
=
27.80
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Gubra AS (STU:PI3) has a Altman Z-Score of 27.80 as of Jun. 27, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Gubra AS and its competitors. This is 28% below median its historical median of 38.73. Over the past decade, Gubra AS's Altman Z-Score has ranged from 10.43 to 39.73. According to the industry distribution chart, Gubra AS ranks #82 out of 934 companies in the Biotechnology industry, placing it in the top 8.8%.
Is Gubra AS's Altman Z-Score too high?
Gubra AS's current Altman Z-Score of 27.80 is 28% below median its 10-year median of 38.73. Over the past 10 years, this metric has ranged from a low of 10.43 to a high of 39.73. The Biotechnology industry median Altman Z-Score is 2.63. Gubra AS's value of 27.80 is 959% above this industry median. Based on the distribution chart, Gubra AS ranks #82 out of 934 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Gubra AS has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gubra AS ranks #82 out of 934 companies for Altman Z-Score. This places Gubra AS in the top 9% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.63. Gubra AS's value of 27.80 is 959% above this benchmark. Historically, Gubra AS's own Altman Z-Score has ranged from 10.43 to 39.73 over the past decade. While the company's 10-year median is 38.73 vs. the industry median of 2.63, Gubra AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.63, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gubra AS's current Altman Z-Score of 27.80 is 959% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Gubra AS and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gubra AS's current Altman Z-Score is 27.80, which is 28% below median its own 10-year median of 38.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Based on GuruFocus' analysis, Gubra AS (STU:PI3) is currently considered Possible Value Trap. The stock's GF Value™ is €381.59, compared to a current price of €43.04 — trading 88.7% below its estimated fair value. The current Altman Z-Score is 27.80, which is 28% below median its 10-year median of 38.73 and 959% above the Biotechnology industry median of 2.63. Gubra AS's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Gubra AS (STU:PI3), the current Altman Z-Score is 27.80 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gubra AS (STU:PI3) Overvalued in 2026?
Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued.
The current stock price of €43.04 is trading 88.7% below its estimated GF Value™ of €381.59.
GuruFocus considers Gubra AS to be Possible Value Trap.
Key valuation signals for STU:PI3:
Altman Z-Score: 27.80 (28% below median its 10-year median of 38.73)
GF Value™: €381.59 vs. price of €43.04 (88.7% below fair value)
Industry Position: 959% above the Biotechnology median (#82 of 934)
No single metric tells the full story. See the STU:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
56GF Score
Get the complete analysis for STU:PI3
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PI3 has been successfully added to your 
